Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Mark Lakshmanan, Brian Rayner, Robert S. Busch, Alan G. Zimmermann, D. Bradley Woodward, Fady T. Botros

The Lancet Diabetes & Endocrinology · 2018 · 635 citations · 22 references

Concepts

References

22